Quest Diagnostics EPS Beats Expectations
Quest Diagnostics reported strong third-quarter earnings driven by acquisitions, with revenue surpassing expectations, though profit margins faced pressure.
Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS. Read why I remain bullish on DGX stock.
Quest Diagnostics Incorporated (NYSE:DGX) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript October 22, 2024 Quest Diagnostics Incorporated beats earnings expectations. Reported EPS is $2.3, expectations were $2.26. Operator: Welcome to the Quest Diagnostics Third Quarter 2024 conference call.
Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025
Quest Diagnostics reports strong Q3 with 8.5% sales growth, raises 2024 revenue guidance to $9.80 billion-$9.85 billion, citing acquisitions and new customer wins.
Quest Diagnostics: Q3 Earnings Snapshot
SECAUCUS, N.J. (AP) — SECAUCUS, N.J. (AP) — Quest Diagnostics Inc. (DGX) on Tuesday reported third-quarter earnings of $226 million. On a per-share basis, the Secaucus, New Jersey-based company said it had net income of $1.99. Earnings, adjusted for one-time gains and costs, were $2.30 per share.
Quest Diagnostics beats quarterly results estimates on diagnostic test demand
Laboratory operator Quest Diagnostics beat Wall Street estimates for third-quarter profit and revenue on Tuesday, helped by robust demand for its diagnostic tests. Demand for diagnostic checkups has grown in recent quarters as more people,
Quest Diagnostics (DGX) Beats Q3 Earnings and Revenue Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $2.22 per share a year ago. These figures are adjusted for non-recurring items.
Quest Diagnostics Has Massive Secular Tailwinds And A Strong Base
Quest Diagnostics benefits from an aging population, driving increased lab testing volumes, and offers 2.0% dividend yield.
US lab operator Quest Diagnostics to launch bird flu test at end of October
Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S.
Quest Diagnostics price target raised to $175 from $163 at Argus
Argus raised the firm’s price target on Quest Diagnostics (DGX) to $175 from $163 and keeps a Buy rating on the shares. The company ...
Quest Diagnostics set to launch a rapid lab test to detect avian influenza A H5 virus
Quest Diagnostics (NYSE:DGX) announced on Wednesday that it will roll out a rapid molecular lab test to detect the avian ...
NJBIZ1d
Quest completes acquisition of OhioHealth’s lab service business
The not-for-profit charitable health group of the United Methodist Church will transition its outreach testing to the ...
Quest Diagnostics: Balanced Risk and Reward Justifies Hold Rating Amid Growth and Margin Challenges
Leerink Partners analyst Michael Cherny has reiterated their neutral stance on DGX stock, giving a Hold rating yesterday. Michael Cherny has ...
360dx1d
Quest Diagnostics Wins CDC Contracts for Avian Flu, Oropouche Testing
Quest has developed a multi-target molecular test for avian influenza A H5 virus that it plans to make available by the end of October.
Quest Diagnostics Posts Upbeat Results, Joins GM, Philip Morris And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling around 50 points on Tuesday. Shares of Quest Diagnostics ...